Compare WAVE & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAVE | IMRN |
|---|---|---|
| Founded | 2011 | 1994 |
| Country | Israel | Australia |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5M | 7.7M |
| IPO Year | 2021 | 2016 |
| Metric | WAVE | IMRN |
|---|---|---|
| Price | $3.18 | $0.90 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $14.75 | N/A |
| AVG Volume (30 Days) | 11.0K | ★ 13.4K |
| Earning Date | 11-03-2026 | 08-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $12.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.48 | $0.68 |
| 52 Week High | $10.87 | $1.99 |
| Indicator | WAVE | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 26.43 | 34.56 |
| Support Level | N/A | $0.75 |
| Resistance Level | $4.92 | $0.89 |
| Average True Range (ATR) | 0.40 | 0.07 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 8.57 | 22.05 |
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient wave energy conversion, or WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographically, it has a presence in Israel, the USA, and Mexico.
Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.